Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Life Sciences Industry Analysis

UpdatedJan 06, 2026
DataAggregated Company Financials
Companies63
  • 7D3.8%
  • 3M11.1%
  • 1Y3.5%
  • YTD3.2%

Over the last 7 days, the Life Sciences industry has remained flat. Furthermore, the industry has been flat for the past year as well. As for the next few years, earnings are expected to grow by 17% per annum.

Industry Valuation and Performance

Has the U.S. Life Sciences Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Tue, 06 Jan 2026US$689.0bUS$145.8bUS$12.4b36.8x55.7x4.7x
Thu, 04 Dec 2025US$668.5bUS$145.8bUS$12.5b36.5x53.6x4.6x
Sat, 01 Nov 2025US$639.2bUS$145.4bUS$12.2b36x52.6x4.4x
Mon, 29 Sep 2025US$552.3bUS$144.3bUS$14.6b29.4x37.9x3.8x
Wed, 27 Aug 2025US$583.2bUS$144.1bUS$14.5b28.8x40.2x4x
Fri, 25 Jul 2025US$565.9bUS$143.6bUS$8.8b41.6x64.4x3.9x
Sun, 22 Jun 2025US$516.2bUS$142.9bUS$9.2b35.3x56.3x3.6x
Tue, 20 May 2025US$519.6bUS$142.7bUS$9.1b33.4x57.2x3.6x
Thu, 17 Apr 2025US$517.3bUS$142.6bUS$10.0b35x52x3.6x
Sat, 15 Mar 2025US$581.3bUS$143.1bUS$9.8b38.6x59.5x4.1x
Mon, 10 Feb 2025US$658.3bUS$143.1bUS$11.1b38.1x59.3x4.6x
Wed, 08 Jan 2025US$673.1bUS$142.4bUS$10.2b43.9x66x4.7x
Fri, 06 Dec 2024US$671.2bUS$142.4bUS$10.2b43.6x65.7x4.7x
Sun, 03 Nov 2024US$689.4bUS$142.2bUS$8.9b39.1x77.3x4.8x
Tue, 01 Oct 2024US$748.6bUS$141.8bUS$8.5b39x88.1x5.3x
Thu, 29 Aug 2024US$745.7bUS$141.8bUS$8.5b37.7x87.8x5.3x
Sat, 27 Jul 2024US$716.0bUS$141.0bUS$12.5b37.3x57.4x5.1x
Mon, 24 Jun 2024US$694.3bUS$141.3bUS$12.2b38.6x57x4.9x
Wed, 22 May 2024US$739.8bUS$141.5bUS$12.4b38.5x59.5x5.2x
Fri, 19 Apr 2024US$682.0bUS$142.0bUS$12.8b41x53.3x4.8x
Sun, 17 Mar 2024US$742.0bUS$142.1bUS$12.8b43.9x57.8x5.2x
Tue, 13 Feb 2024US$709.9bUS$141.9bUS$12.7b39.2x55.8x5x
Thu, 11 Jan 2024US$692.8bUS$153.9bUS$14.2b36.6x48.9x4.5x
Sat, 09 Dec 2023US$648.8bUS$153.7bUS$14.0b35.2x46.3x4.2x
Mon, 06 Nov 2023US$595.2bUS$153.9bUS$11.0b31.5x54x3.9x
Wed, 04 Oct 2023US$640.4bUS$154.6bUS$11.2b32.3x57.2x4.1x
Fri, 01 Sep 2023US$733.5bUS$154.6bUS$11.2b32.9x65.4x4.7x
Sun, 30 Jul 2023US$734.3bUS$154.7bUS$11.6b31.5x63.2x4.7x
Tue, 27 Jun 2023US$687.9bUS$152.4bUS$12.5b29.3x55x4.5x
Thu, 25 May 2023US$671.4bUS$152.2bUS$12.5b27.8x53.7x4.4x
Sat, 22 Apr 2023US$728.5bUS$154.6bUS$10.8b29.9x67.4x4.7x
Mon, 20 Mar 2023US$700.9bUS$154.5bUS$10.8b27.3x64.8x4.5x
Wed, 15 Feb 2023US$749.4bUS$154.2bUS$8.6b32.4x87.2x4.9x
Fri, 13 Jan 2023US$756.5bUS$155.3bUS$8.5b30.4x88.7x4.9x
Price to Earnings Ratio

88.7x


Total Market Cap: US$756.5bTotal Earnings: US$8.5bTotal Revenue: US$155.3bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Life Sciences Industry Price to Earnings3Y Average 60x202420252026
Current Industry PE
  • Investors are pessimistic on the American Life Sciences industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 54.0x which is lower than its 3-year average PE of 60.0x.
  • The industry is trading close to its 3-year average PS ratio of 4.5x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences industry have grown 13% per year over the last three years.
  • Meanwhile revenues for these companies have declined 2.1% per year.
  • This means that less sales are being generated overall, but since cost of doing business is lower, profits have been increasing.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market0.48%
Healthcare-0.16%
Life Sciences3.77%
Clinical Research and Equipment3.77%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
TMO Thermo Fisher ScientificUS$611.204.8%
+US$10.4b		12.0%PE35x
DHR DanaherUS$235.362.0%
+US$3.3b		-1.6%PE47.5x
A Agilent TechnologiesUS$142.933.9%
+US$1.5b		4.0%PE31.1x
ILMN IlluminaUS$141.336.5%
+US$1.3b		1.6%PE30.7x
IQV IQVIA HoldingsUS$234.593.0%
+US$1.2b		15.8%PE31.1x

Latest News

TMO
US$611.20
Thermo Fisher Scientific
7D
4.8%
1Y
12.0%

Unpleasant Surprises Could Be In Store For Thermo Fisher Scientific Inc.'s (NYSE:TMO) Shares

Jan 05
Unpleasant Surprises Could Be In Store For Thermo Fisher Scientific Inc.'s (NYSE:TMO) Shares
TEM
US$64.70
Tempus AI
7D
7.1%
1Y
66.4%
A
US$142.93
Agilent Technologies
7D
3.9%
1Y
4.0%
FTRE
US$16.62
Fortrea Holdings
7D
-4.4%
1Y
-13.9%

FTRE: Rapid Share Gains Will Be Tested By Leadership Execution Risks

Analysts have nudged their average price target on Fortrea Holdings higher, from $12.07 to $13.25, citing encouraging early progress under new leadership, a steady Q3 book-to-bill backdrop, and signs that contract research and healthcare utilization trends may be stabilizing into 2026. Analyst Commentary Recent research updates reflect a cautiously constructive stance on Fortrea, with incremental target price hikes tied to operational progress and a stabilizing industry backdrop.
ICLR
US$197.58
ICON
7D
8.0%
1Y
-11.2%

ICLR: Strong Bookings And RFP Momentum Will Support Long Term Upside

We nudge our ICON price target slightly higher to approximately $206.38 from about $206.19, as analysts balance continued concerns around 2026 margin pressure and pricing headwinds with updated post Q3 models and confidence that stronger gross bookings and RFP flow can support a healthier long term growth profile. Analyst Commentary Street research reflects a mixed but generally constructive stance on ICON, with price targets converging around the low to mid $200 range and a split between Hold and Outperform ratings.
LFCR
US$7.80
Lifecore Biomedical
7D
-3.6%
1Y
32.0%

LFCR: New Manufacturing Agreements Will Support Steadier Outlook With Balanced Prospects

Analysts have modestly revised their price target for Lifecore Biomedical to about $8.75 per share, citing slightly improved long term profit margin assumptions and a marginally lower discount rate that together support a steadier valuation outlook. What's in the News Lifecore signed a CDMO master services agreement with a new large global pharmaceutical customer to transfer commercial supply of an injectable product from overseas facilities to Lifecore, with potential for the partner to become one of its top five commercial customers (Key Developments).
IQV
US$234.59
IQVIA Holdings
7D
3.0%
1Y
15.8%

IQV Will Balance Recovery In Cancellations With Ongoing Execution And Margin Risks

The analyst-derived fair value estimate for IQVIA Holdings has been raised from $168.00 to approximately $223.24 per share, as analysts point to improving cancellation trends, a clearer earnings reacceleration path, and a moderately better environment supporting higher long-term growth and valuation multiples. Analyst Commentary Recent Street research on IQVIA reflects a more constructive long term narrative, but with a notable split between bullish and more cautious views on the stock’s risk reward profile.
DHR
US$235.36
Danaher
7D
2.0%
1Y
-1.6%

DHR: Share Repurchases Will Support Premium Multiple As Life Sciences Demand Recovers

Analysts modestly raised their blended fair value estimate for Danaher to about $258 from roughly $256, reflecting slightly lower discount rate and higher future multiple assumptions, even as they trim official price targets toward $220 amid ongoing uncertainty around the pace of life sciences and diagnostics recovery. Analyst Commentary Analysts broadly agree that Danaher's premium valuation assumes a reacceleration of growth across life sciences and diagnostics, but they remain divided on how quickly fundamentals will normalize versus the lingering headwinds in key end markets.
ADPT
US$16.17
Adaptive Biotechnologies
7D
-1.5%
1Y
127.7%
ABCL
US$3.43
AbCellera Biologics
7D
-0.6%
1Y
4.6%
OABI
US$1.85
OmniAb
7D
-0.5%
1Y
-49.2%

OABI: Future Platform Launch And Partnerships Will Drive Revenue Upside

Narrative Update on OmniAb Analysts have maintained their price target on OmniAb at approximately 7.33 dollars, reflecting only marginal adjustments to the discount rate and profitability assumptions, while leaving their long-term growth outlook largely unchanged. What's in the News OmniAb plans to debut its new OmniUltra trademark transgenic chicken platform in December 2025 at the Antibody Engineering & Therapeutics conference.
MTD
US$1,446.63
Mettler-Toledo International
7D
2.3%
1Y
15.3%

MTD: Share Repurchases And Modest M&A Will Support Measured Returns Ahead

Analysts have nudged their price target on Mettler-Toledo International slightly higher, raising fair value by about 0.2 percent to approximately 1,496 dollars. They have refined their models to reflect marginally lower discount rates and steady expectations for revenue growth, profit margins, and future valuation multiples.
ILMN
US$141.33
Illumina
7D
6.5%
1Y
1.6%

ILMN: China Export Risks Will Likely Limit Upside Despite Recent Optimism

Analysts raised our implied fair value estimate for Illumina by 7 dollars to 80 dollars per share. This reflects higher revenue growth and profit margin expectations following better than anticipated quarterly results and a series of upward price target revisions across the Street, despite lingering visibility concerns.
NAGE
US$6.45
Niagen Bioscience
7D
-0.5%
1Y
19.4%

Niagen Bioscience: A Breakout Quarter That Now Faces Its Biggest Market Shift In Years

Nov 15
MXCT
US$1.55
MaxCyte
7D
-0.6%
1Y
-64.6%
NAUT
US$1.89
Nautilus Biotechnology
7D
-1.0%
1Y
9.9%